DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers.

Abstract:

:Microarrays for gene expression profiling are rapidly becoming important research tools for the identification of novel markers, for example, for novel classification of leukemias and lymphomas. Here, we review the considerations and infrastructure for microarray experiments. These considerations are illustrated via a microarray-based comparison of gene expression profiles of paired diagnosis-relapse samples from patients with precursor-B acute lymphoblastic leukemia (ALL), who relapsed during therapy or after completion of treatment. Initial experiments showed that several seemingly differentially expressed genes were actually derived from contaminating non-leukemic cells, particularly myeloid cells and T-lymphocytes. Therefore, we purified the ALL cells of the diagnosis and relapse samples if their frequency was lower than 95%. Furthermore, we observed in earlier studies that extra RNA amplification leads to skewing of particular gene transcripts. Sufficient (non-amplified) RNA of purified and paired diagnosis-relapse samples was obtained from only seven cases. The gene expression profiles were evaluated with Affymetrix U95A chips containing 12 600 human genes. These diagnosis-relapse comparisons revealed only a small number of genes (n=6) that differed significantly in expression: mostly signaling molecules and transcription factors involved in cell proliferation and cell survival were highly upregulated at relapse, but we did not observe any increase in drug-resistance markers. This finding fits with the observation that tumors with a high proliferation index have a poor prognosis. The genes that changed between diagnosis and relapse are currently not in use as diagnostic or disease progression markers, but represent potential new markers for such applications. Leukemia (2003) 17, 1324-1332. doi:10.1038/sj.leu.2402974

journal_name

Leukemia

journal_title

Leukemia

authors

Staal FJ,van der Burg M,Wessels LF,Barendregt BH,Baert MR,van den Burg CM,van Huffel C,Langerak AW,van der Velden VH,Reinders MJ,van Dongen JJ

doi

10.1038/sj.leu.2402974

subject

Has Abstract

pub_date

2003-07-01 00:00:00

pages

1324-32

issue

7

eissn

0887-6924

issn

1476-5551

pii

2402974

journal_volume

17

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia.

    abstract::Human cytomegalovirus (CMV) infections and relapse of disease remain major problems after allogeneic stem cell transplantation (allo-SCT), in particular in combination with CMV-negative donors or cordblood transplantations. Recent data suggest a paradoxical association between CMV reactivation after allo-SCT and reduc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.374

    authors: Scheper W,van Dorp S,Kersting S,Pietersma F,Lindemans C,Hol S,Heijhuurs S,Sebestyen Z,Gründer C,Marcu-Malina V,Marchant A,Donner C,Plachter B,Vermijlen D,van Baarle D,Kuball J

    更新日期:2013-06-01 00:00:00

  • Cytokine enhancement of immunogenicity in chronic myeloid leukaemia.

    abstract::Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic respon...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400858

    authors: Coleman S,Throp D,Fisher J,Bailey-Wood R,Lim SH

    更新日期:1997-12-01 00:00:00

  • Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism.

    abstract::Mucosa-associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the nuclear factor (NF)-kappaB pathway. Gastric MALT lymphomas harboring such translocations usually do not respond to Helicobacter pyl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.118

    authors: Hamoudi RA,Appert A,Ye H,Ruskone-Fourmestraux A,Streubel B,Chott A,Raderer M,Gong L,Wlodarska I,De Wolf-Peeters C,MacLennan KA,de Leval L,Isaacson PG,Du MQ

    更新日期:2010-08-01 00:00:00

  • ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.

    abstract::Primary myelofibrosis (PMF) is a hematopoietic stem cell (HSC) disease, characterized by aberrant differentiation of all myeloid lineages and profound disruption of the bone marrow niche. PMF samples carry several mutations, but their cell origin and hierarchy in regulating the different waves of clonal and aberrant m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0159-0

    authors: Triviai I,Zeschke S,Rentel J,Spanakis M,Scherer T,Gabdoulline R,Panagiota V,Thol F,Heuser M,Stocking C,Kröger N

    更新日期:2019-01-01 00:00:00

  • Current recommendations for positive controls in RT-PCR assays.

    abstract::The choice of adequate controls for reverse transcriptase (RT-) PCR analysis has been the focus of a debate pursued in Leukemia over the past 3 years. Twenty-six authors from 15 different centers contributed to the Debate, and the points presented have been carefully evaluated. This survey reviews the issues discussed...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2402133

    authors: Lion T

    更新日期:2001-07-01 00:00:00

  • Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

    abstract::Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring sideroblasts (RS). RS is a cardinal feature of refractory anemia with RS (RARS) and RARS with marked thrombocytosis (RARS/-T). Mutations in SF3B1, a member of ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.170

    authors: Visconte V,Avishai N,Mahfouz R,Tabarroki A,Cowen J,Sharghi-Moshtaghin R,Hitomi M,Rogers HJ,Hasrouni E,Phillips J,Sekeres MA,Heuer AH,Saunthararajah Y,Barnard J,Tiu RV

    更新日期:2015-01-01 00:00:00

  • Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature.

    abstract::During the 15 year period 1975-1989, 74 cases of chronic myeloproliferative disorder (CMPD) were cytogenetically analyzed in our department. Thirty patients had polycythemia vera (PV), 23 had idiopathic myelofibrosis (MFS), 15 had idiopathic thrombocythemia (IT), and six had unclassifiable CMPD (UCMPD). The overall fr...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Mertens F,Johansson B,Heim S,Kristoffersson U,Mitelman F

    更新日期:1991-03-01 00:00:00

  • Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma.

    abstract::Osteolysis resulting in extensive bone damage is a major clinical manifestation of patients with multiple myeloma (MM). The mechanisms of bone resorption in MM are incompletely understood. The final pathway is the generation of activated osteoclasts within bone marrow (BM) microenvironment. To investigate the mechanis...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gregoretti MG,Bergui L,Aragno M,Cremona O,Marchisio PC,Caligaris-Cappio F

    更新日期:1995-08-01 00:00:00

  • Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

    abstract::We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfav...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.234

    authors: Caramazza D,Begna KH,Gangat N,Vaidya R,Siragusa S,Van Dyke DL,Hanson C,Pardanani A,Tefferi A

    更新日期:2011-01-01 00:00:00

  • Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation.

    abstract::Cord blood (CB) is an attractive alternative to bone marrow or peripheral blood as a source of transplantable hematopoietic tissue. However, because of the reduced volume, the stem cell content is limited; therefore its use as a graft for adult patients might require ex vivo manipulations. Two systems have been descri...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401003

    authors: Piacibello W,Sanavio F,Garetto L,Severino A,Dané A,Gammaitoni L,Aglietta M

    更新日期:1998-05-01 00:00:00

  • Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer.

    abstract::Therapy-related myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML) are serious complications of chemotherapy and radiotherapy for cancer. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be associated with an increased incidence of these complications. The frequency o...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402631

    authors: Nichols G,de Castro K,Wei LX,Griffin M,Lin N,Oratzi A,Murty VV,Troxel A,Vahdat L,Hesdorffer C

    更新日期:2002-09-01 00:00:00

  • In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.

    abstract::We report here the case of a 55-year-old patient with chronic granular lymphocyte disorder associated with moderate neutropenia. The majority of peripheral blood lymphocytes displayed a CD3-, CD8-, CD16+, CD56(NKH1)- phenotype. The patient's cells showed high spontaneous cytotoxic activity against K562 targets and dev...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bayle C,Vitté-Mony I,Lang P,Pico J,Hercend T,Bertoglio J

    更新日期:1992-05-01 00:00:00

  • DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.

    abstract::We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404653

    authors: Suela J,Alvarez S,Cifuentes F,Largo C,Ferreira BI,Blesa D,Ardanaz M,García R,Marquez JA,Odero MD,Calasanz MJ,Cigudosa JC

    更新日期:2007-06-01 00:00:00

  • Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

    abstract::Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0334-3

    authors: Saenz DT,Fiskus W,Manshouri T,Mill CP,Qian Y,Raina K,Rajapakshe K,Coarfa C,Soldi R,Bose P,Borthakur G,Kadia TM,Khoury JD,Masarova L,Nowak AJ,Sun B,Saenz DN,Kornblau SM,Horrigan S,Sharma S,Qiu P,Crews CM,Versto

    更新日期:2019-06-01 00:00:00

  • A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

    abstract::The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.225

    authors: Burnett AK,Russell NH,Hills RK,Kell J,Nielsen OJ,Dennis M,Cahalin P,Pocock C,Ali S,Burns S,Freeman S,Milligan D,Clark RE

    更新日期:2017-02-01 00:00:00

  • Cellular and molecular studies on the early stages of human hematopoietic differentiation in culture of pure progenitors.

    abstract::Methodology has been developed that enables virtually complete purification and recovery of early hematopoietic progenitors from human adult blood, a minority of which is multipotent and endowed with self-renewal capacities, i.e., exhibits stem cell properties. This report briefly reviews: (i) the key steps involved i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Pelosi E,Testa U,Gabbianelli M,Valtieri M,Montesoro E,Samoggia P,Mastroberardino G,Isacchi G,Peschle C

    更新日期:1992-11-01 00:00:00

  • A novel CD10-positive erythroid cell line, RM10, established from a patient with chronic myelogenous leukemia.

    abstract::A novel erythroid cell line, RM10, was established from a long-term bone marrow culture of a patient with chronic myelogenous leukemia (CML). RM10 cells were positive for periodic acid Schiff (PAS), but negative for peroxidase and dual esterase. RM10 cells had la, pre B (CD10), myeloid (CD13, CD14, CD33) and erythroid...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hirata J,Sato H,Takahira H,Shiokawa S,Endo T,Nishimura J,Katsuno M,Masuda S,Sasaki R,Fukumaki Y

    更新日期:1990-05-01 00:00:00

  • Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML.

    abstract::t(8;21)(q22;q22) is the most frequently observed karyotypic abnormality associated with acute myeloid leukemia (AML), especially in FAB M2. Clinically, this type of AML often shows eosinophilia and has a high complete remission rate with conventional chemotherapy. t(8;21) AML is also frequently associated with additio...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2402871

    authors: Nishii K,Usui E,Katayama N,Lorenzo F 5th,Nakase K,Kobayashi T,Miwa H,Mizutani M,Tanaka I,Nasu K,Dohy H,Kyo T,Taniwaki M,Ueda T,Kita K,Shiku H

    更新日期:2003-04-01 00:00:00

  • Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

    abstract::This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with c...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2017.327

    authors: Bringhen S,D'Agostino M,De Paoli L,Montefusco V,Liberati AM,Galieni P,Grammatico S,Muccio VE,Esma F,De Angelis C,Musto P,Ballanti S,Offidani M,Petrucci MT,Gaidano G,Corradini P,Palumbo A,Sonneveld P,Boccadoro M

    更新日期:2018-04-01 00:00:00

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

    abstract::We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2405014

    authors: de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

    更新日期:2008-02-01 00:00:00

  • Clinical activity of arsenic trioxide for the treatment of multiple myeloma.

    abstract::Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, rela...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2402599

    authors: Munshi NC,Tricot G,Desikan R,Badros A,Zangari M,Toor A,Morris C,Anaissie E,Barlogie B

    更新日期:2002-09-01 00:00:00

  • Toward a new paradigm of cell plasticity.

    abstract::The standard paradigm of embryologic development and adult tissue reconstitution posits unidirectional, hierarchical lineages. The presumed mechanisms underlying these differentiative pathways are gene restrictions, such as methylation and heterochromatin formation, which are commonly described as irreversible. Howeve...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2402445

    authors: Theise ND,Krause DS

    更新日期:2002-04-01 00:00:00

  • Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia.

    abstract::We have analyzed the expression of Tdt and CD7 in 335 cases of unequivocal acute myeloid leukemia (AML). Tdt was expressed in 80 (25%) of 321 evaluable cases. Twenty-six of 77 (34%) Tdt+ patients assessable for response, entered complete remission (CR) vs 121 of 209 (58%) Tdt- cases (P < 0.001). CD7 was expressed in 1...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401067

    authors: Venditti A,Del Poeta G,Buccisano F,Tamburini A,Cox-Froncillo MC,Aronica G,Bruno A,Del Moro B,Epiceno AM,Battaglia A,Forte L,Postorino M,Cordero V,Santinelli S,Amadori S

    更新日期:1998-07-01 00:00:00

  • Targeting MYC in multiple myeloma.

    abstract::Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC locus and deregulation of upstream pathways such as IRF4, DIS3/LIN28B/...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-018-0036-x

    authors: Jovanović KK,Roche-Lestienne C,Ghobrial IM,Facon T,Quesnel B,Manier S

    更新日期:2018-06-01 00:00:00

  • Contact inhibition-induced inactivation of the cyclin D-dependent kinase in rat fibroblast cell line, 3Y1.

    abstract::Inhibitory proteins for Cdks (CKIs) are involved in cell cycle arrest induced by anti-mitotic factors, chemicals, or DNA damage in mammalian cells. High cell density also induces cell cycle arrest with unreplicated genomic DNA even in the presence of mitotic dose of the growth factors, termed contact inhibition. Altho...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kato A,Takahashi H,Takahashi Y,Matsushime H

    更新日期:1997-04-01 00:00:00

  • Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.

    abstract::In this study, the abilities of constitutive and conditional forms of the three Raf kinases to abrogate the cytokine dependency of FDC-P1 cells were examined. The constitutively active forms (delta) of all three Raf kinases were fused to the hormone-binding domain of the estrogen receptor (ER), rendering their activit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401720

    authors: Hoyle PE,Moye PW,Steelman LS,Blalock WL,Franklin RA,Pearce M,Cherwinski H,Bosch E,McMahon M,McCubrey JA

    更新日期:2000-04-01 00:00:00

  • Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

    abstract::The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 (n=231), TT2 (n=668) without or with thalidomide and TT3 with added bortezomib (n=303) have been reported. An...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.160

    authors: Usmani SZ,Crowley J,Hoering A,Mitchell A,Waheed S,Nair B,AlSayed Y,Vanrhee F,Barlogie B

    更新日期:2013-01-01 00:00:00

  • Interferon alpha in the therapy of multiple myeloma.

    abstract::Response rates of 20% were achieved when interferon alpha (IFN) was applied as single agent treatment for multiple myeloma. A synergistic activity was observed when IFN was combined with chemotherapeutic agents in vitro and in vivo. These observations led to a series of randomized trials comparing chemotherapy alone w...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Gisslinger H

    更新日期:1997-12-01 00:00:00

  • Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes.

    abstract::The expression of the myeloperoxidase (MPO) gene was studied, by means of Northern blot analysis in 14 cases of acute myeloid leukemia (AML), 11 cases of chronic myeloid leukemia (CML), and 6 cases of CML blast crisis, and in HL60 cells before and after induction of terminal differentiation with retinoic acid (RA), ph...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ferrari S,Tagliafico E,Ceccherelli G,Selleri L,Calabretta B,Donelli A,Temperani P,Sarti M,Sacchi S,Emilia G

    更新日期:1989-06-01 00:00:00

  • In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.

    abstract::APL-associated hemostasis disorders result from at least two distinct mechanisms due to the release of procoagulant activities and plasminogen activators from the leukemic cells. These two mechanisms (thrombin activation and plasmin activation) may cleave the fibrinogen molecule, but their respective roles in low fibr...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dombret H,Scrobohaci ML,Daniel MT,Micléa JM,Castaigne S,Chomienne C,Fenaux P,Degos L

    更新日期:1995-01-01 00:00:00